Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473838 | 1.00 | KDM4E (0.48) | KDM4EMEN1KMT2ALMNAMMP8 | |
| SCHEMBL6473834 | 1.00 | KDM4E (0.48) | KDM4EMEN1KMT2ALMNAMMP8 | |
| SCHEMBL27233049 | 0.81 | ALDH1A1 (0.56) | KDM4EMEN1KMT2ALMNAMMP8 | |
| SCHEMBL542561 | 0.78 | LMNA (0.53) | MEN1KMT2ALMNAAKR1B1TNKS | |
| SCHEMBL20134878 | 0.78 | LMNA (0.53) | MEN1KMT2ALMNAAKR1B1TNKS | |
| SCHEMBL7102532 | 0.77 | LMNA (0.47) | LMNAAKR1B1 | |
| SCHEMBL6135313 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNAAKR1B1TNKS | |
| SCHEMBL17054772 | 0.77 | MEN1 (0.55) | MEN1KMT2ALMNATNKSMMP2 | |
| SCHEMBL17570773 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNAAKR1B1TNKS | |
| SCHEMBL204119 | 0.77 | LMNA (0.51) | MEN1KMT2ALMNAAKR1B1TNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651872-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | Septerna, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024155601-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE TO TREAT HYPOPARATHYROIDISM AND OSTEOPOROSIS | SEPTERNA, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340540-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | KOWA COMPANY, LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2098515-A1 | SUBSTITUTED CARBINOL COMPOUND | Kowa Company. Ltd. (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-6838439-B2 | Heterocytes as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-04 | — | — | US | disclosed |
| EP-0842945-B1 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AG (DE) | 2003-02-19 | — | — | EP | disclosed |
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-05-30 | — | — | US | disclosed |
| US-6191282-B1 | DERIVATIVES OF 5-MEMBERED NITROGEN CONTAINING HETEROCYCLIC RING IS USED AS ANTICARCINOGENIC AGENT AND ANTICOAGULANT | HOECHST MARION ROUSSEL (DE) | 2001-02-20 | — | — | US | disclosed |
| US-5981492-A | ADMINISTERED TO THE PATIENT TO INHIBIT THROMBOCYTE AGGREGATION, THE METASTASIZATION OF CARCINOMA CELLS, THE BINDING OF OSTEOCLASTS TO THE BONE SURFACE, OR FOR THE TREATMENT OF THROMBOSES | HOECHST AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| EP-0842945-A2 | Heterocycles as inhibitors of leukocyte adhesion and as antagonists of VLA-4 | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-20 | — | — | EP | disclosed |
| EP-0729460-A1 | SUBSTITUTED 5-RING HETEROCYCLES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995014008-A1 | SUBSTITUTED 5-RING HETEROCYCLES, THEIR PREPARATION AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065391-A1 | Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists | VCAM1, ICAM1, ITGB4 | KDM4E 2308/4885MEN1 3726/4885KMT2A 2036/4885 |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885MEN1 2491/4885KMT2A 206/4885 |
| US-20100048610-A1 | CARBINOL DERIVATIVES HAVING CYCLIC LINKER | NR1H2, NR1H3, LDLR | KDM4E 4240/4885MEN1 3823/4885KMT2A 2383/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | KDM4E 391/4885MEN1 2491/4885KMT2A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.